# C9orf40

## Overview
C9orf40, or chromosome 9 open reading frame 40, is a gene located on the long arm of chromosome 9 at position 9q21.13. It encodes a protein that is currently uncharacterized, meaning its specific biological functions and mechanisms remain largely unknown (Ershov2023Uncharacterized). Despite the limited understanding of the protein's role, C9orf40 has been implicated in various clinical contexts, particularly in cancer and genetic syndromes. The gene's expression has been associated with immune cell infiltration in tumors, suggesting a potential involvement in immune response pathways, such as the NF-kappa B signaling pathway (Ershov2023Uncharacterized). Additionally, C9orf40 is located within a genomic region linked to a microdeletion syndrome, although its direct contribution to the syndrome's phenotype is not well-defined (BoudryLabis2013A; De2023New). Further research is needed to elucidate the precise functions and clinical significance of the C9orf40 protein.

## Clinical Significance
The C9orf40 gene has been implicated in various clinical contexts, particularly in relation to cancer and genetic syndromes. In thymoma, the overexpression of C9orf40 is associated with tumor immune cell infiltration, suggesting a role in the immune response within the tumor microenvironment. This overexpression is linked to the NF-kappa B signaling pathway, which is involved in inflammation and immune responses, although specific details on patient outcomes or treatment responses are not provided (Ershov2023Uncharacterized).

C9orf40 is also located within the 9q21.13 region, which is associated with a microdeletion syndrome characterized by mental retardation, speech delay, epilepsy, and distinct facial features. While the clinical significance of C9orf40 itself in this syndrome is not explicitly detailed, it is part of the genomic region affected by the microdeletion. The syndrome is primarily linked to other genes in the region, such as RORB, which are considered more directly responsible for the neurological phenotype observed in patients (BoudryLabis2013A; De2023New).

Overall, while C9orf40 is associated with certain clinical conditions, its specific role and significance in these contexts require further investigation.


## References


[1. (BoudryLabis2013A) Elise Boudry-Labis, Bénédicte Demeer, Cédric Le Caignec, Bertrand Isidor, Michèle Mathieu-Dramard, Ghislaine Plessis, Alice M. George, Juliet Taylor, Salim Aftimos, Adelheid Wiemer-Kruel, Jürgen Kohlhase, Göran Annerén, Helen Firth, Ingrid Simonic, Joris Vermeesch, Ann-Charlotte Thuresson, Henri Copin, Donald R. Love, and Joris Andrieux. A novel microdeletion syndrome at 9q21.13 characterised by mental retardation, speech delay, epilepsy and characteristic facial features. European Journal of Medical Genetics, 56(3):163–170, March 2013. URL: http://dx.doi.org/10.1016/j.ejmg.2012.12.006, doi:10.1016/j.ejmg.2012.12.006. This article has 32 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ejmg.2012.12.006)

[2. (De2023New) Alessandro De Falco, Achille Iolascon, Flora Ascione, and Carmelo Piscopo. New insights in 9q21.13 microdeletion syndrome: genotype–phenotype correlation of 28 patients. Genes, 14(5):1116, May 2023. URL: http://dx.doi.org/10.3390/genes14051116, doi:10.3390/genes14051116. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/genes14051116)

[3. (Ershov2023Uncharacterized) Pavel Ershov, Evgeniy Yablokov, Yuri Mezentsev, and Alexis Ivanov. Uncharacterized proteins cxorfx: subinteractome analysis and prognostic significance in cancers. International Journal of Molecular Sciences, 24(12):10190, June 2023. URL: http://dx.doi.org/10.3390/ijms241210190, doi:10.3390/ijms241210190. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms241210190)